An experimental medication that could become the first drug derived from a marijuana plant approved in the US, received a boost from Food and Drug Administration (FDA) staff. The treatment’s maker, UK company GW Pharmaceuticals, provided "substantial evidence" of the drug’s effectiveness, FDA staff said in a report released Tuesday. The medication would treat seizures associated with two rare forms of epilepsy that typically affect children, according to the report. Although the medication appears to have an increased risk of liver injury, it could be managed, the report said. "The risk-benefit profile established by the data in the application appears to support approval of cannabidiol," FDA staff wrote. GW Pharma’s US depositary receipts rose 4.5% to $126 in early trading in New York. Later this week, a meeting of outside agency advisers will weigh in on the treatment. The drug is made from a compound in the marijuana plant called cannabidiol, a different chemical from tetrahydroc...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now